# A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

> **NCT07015242** · PHASE2 · RECRUITING · sponsor: **Juno Therapeutics, Inc., a Bristol-Myers Squibb Company** · enrollment: 65 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Methotrexate
- **DRUG:** Procarbazine
- **DRUG:** Temozolomide
- **BIOLOGICAL:** Liso-cel
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Calcium folinate

## Key facts

- **NCT ID:** NCT07015242
- **Lead sponsor:** Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2028-01-09
- **Final completion:** 2028-12-10
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07015242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07015242, "A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07015242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*